Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2?Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Stock Information for Zymeworks Inc.
Loading
Please wait while we load your information from QuoteMedia.